Business

Our history

This is the story of how pioneering research has developed a diagnostic aid helping healthcare professionals in Scandinavia, Germany and Austria on the diagnostic pathway of significant coronary artery disease.

The Acarix Story

2007

  • The technology developed at Aalborg University receives the Medicoprisen award in Denmark and is incubated in the Coloplast Innovation Center.

2008

  • The project receives MDKK 6.8 in funding from Højteknologifonden (the High Tech Fund) in Denmark.

2009

  • The project is turned into a separate company, and Acarix A/S is founded. Coloplast, Aalborg University and the individual founders are shareholders.

2010

  • Sunstone Capital, SEED Capital and Seventure invest a total of MDKK 21 in the company.

  • The first prototype is completed and CAD – CP002 studies are conducted on high-risk groups.

  • Acarix receives MDKK 55.3 in funding from the Market Development Fund in Denmark.

2013

  • A new share issue of MDKK 27 is carried out.

  • Acarix completes the registry study of high-risk groups for CAD – AC003.

2014

  • A new share issue of MDKK 18.7 is carried out.

2015

  • The CADScor®System receives its CE marking and is ready for commercialization in Europe.

2016

  • The CADScor®System transitions from prototype to production of the final product.

  • Registration of the major Dan-NICAD study comprising 1,675 patients is completed.

  • Strategic investor Puhua Jingxin agrees on a major investment and discusses collaboration on the Chinese market.

  • The CADScor®System receives regulatory approval in Canada.

  • Completed IPO of new shares and listing on Nasdaq First North Premier Stockholm.

2017

  • Direct sales force in place in Germany, Sweden and Denmark.

  • First sales in Germany, Sweden, Denmark and Austria.

2018

  • Enrolment in Dan-NICADII begins.

  • Enrolment in Seismo begins.

  • In commercial use. CADScor®System tests have diagnosed more than 1,000 patients.